These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 12352462

  • 1. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells.
    Peehl DM, Seto E, Hsu JY, Feldman D.
    J Urol; 2002 Oct; 168(4 Pt 1):1583-8. PubMed ID: 12352462
    [Abstract] [Full Text] [Related]

  • 2. Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
    Peehl DM, Seto E, Feldman D.
    Urology; 2001 Aug; 58(2 Suppl 1):123-6. PubMed ID: 11502466
    [Abstract] [Full Text] [Related]

  • 3. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 4. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells.
    Miettinen S, Ahonen MH, Lou YR, Manninen T, Tuohimaa P, Syvälä H, Ylikomi T.
    Int J Cancer; 2004 Jan 20; 108(3):367-73. PubMed ID: 14648702
    [Abstract] [Full Text] [Related]

  • 5. Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells.
    Segersten U, Björklund P, Hellman P, Akerström G, Westin G.
    Clin Endocrinol (Oxf); 2007 Mar 20; 66(3):399-404. PubMed ID: 17302875
    [Abstract] [Full Text] [Related]

  • 6. Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase.
    Roy S, Martel J, Tenenhouse HS.
    J Bone Miner Res; 1995 Dec 20; 10(12):1951-9. PubMed ID: 8619376
    [Abstract] [Full Text] [Related]

  • 7. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
    Miller GJ, Stapleton GE, Hedlund TE, Moffat KA.
    Clin Cancer Res; 1995 Sep 20; 1(9):997-1003. PubMed ID: 9816072
    [Abstract] [Full Text] [Related]

  • 8. CYP24A1 inhibition enhances the antitumor activity of calcitriol.
    Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, Johnson CS.
    Endocrinology; 2010 Sep 20; 151(9):4301-12. PubMed ID: 20591973
    [Abstract] [Full Text] [Related]

  • 9. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH, Zhao XY, Holloway L, Feldman D.
    Endocrinology; 1999 May 20; 140(5):2071-6. PubMed ID: 10218956
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression.
    Krishnan AV, Peehl DM, Feldman D.
    J Cell Biochem; 2003 Feb 01; 88(2):363-71. PubMed ID: 12520538
    [Abstract] [Full Text] [Related]

  • 11. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
    Perez-Stable CM, Schwartz GG, Farinas A, Finegold M, Binderup L, Howard GA, Roos BA.
    Cancer Epidemiol Biomarkers Prev; 2002 Jun 01; 11(6):555-63. PubMed ID: 12050097
    [Abstract] [Full Text] [Related]

  • 12. The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3).
    Wang X, Chen X, Akhter J, Morris DL.
    Br J Urol; 1997 Aug 01; 80(2):260-2. PubMed ID: 9284199
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
    Yee SW, Campbell MJ, Simons C.
    J Steroid Biochem Mol Biol; 2006 Mar 01; 98(4-5):228-35. PubMed ID: 16483768
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R.
    Clin Cancer Res; 2004 Dec 01; 10(23):8018-27. PubMed ID: 15585637
    [Abstract] [Full Text] [Related]

  • 15. The role of Vitamin D3 metabolism in prostate cancer.
    Lou YR, Qiao S, Talonpoika R, Syvälä H, Tuohimaa P.
    J Steroid Biochem Mol Biol; 2004 Nov 01; 92(4):317-25. PubMed ID: 15663995
    [Abstract] [Full Text] [Related]

  • 16. 25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells.
    Lou YR, Laaksi I, Syvälä H, Bläuer M, Tammela TL, Ylikomi T, Tuohimaa P.
    FASEB J; 2004 Feb 01; 18(2):332-4. PubMed ID: 14657005
    [Abstract] [Full Text] [Related]

  • 17. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
    Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ.
    Oncogene; 2001 Apr 05; 20(15):1860-72. PubMed ID: 11313934
    [Abstract] [Full Text] [Related]

  • 18. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
    Iglesias-Gato D, Zheng S, Flanagan JN, Jiang L, Kittaka A, Sakaki T, Yamamoto K, Itoh T, Lebrasseur NK, Norstedt G, Chen TC.
    J Steroid Biochem Mol Biol; 2011 Nov 05; 127(3-5):269-75. PubMed ID: 21911059
    [Abstract] [Full Text] [Related]

  • 19. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
    Bareis P, Kállay E, Bischof MG, Bises G, Hofer H, Pötzi C, Manhardt T, Bland R, Cross HS.
    Exp Cell Res; 2002 Jun 10; 276(2):320-7. PubMed ID: 12027461
    [Abstract] [Full Text] [Related]

  • 20. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 10; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.